0001140361-20-010790.txt : 20200506 0001140361-20-010790.hdr.sgml : 20200506 20200506111538 ACCESSION NUMBER: 0001140361-20-010790 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200506 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 20851679 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 8-K 1 form8k.htm 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported):  May 6, 2020
 
IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)
 
000-19125
  
33-0336973
(Commission File No.)
  
(IRS Employer Identification No.)

2855 Gazelle Court
Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)
 
Registrant’s telephone number, including area code: (760) 931-9200

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading symbol
  
Name of each exchange on which registered
Common Stock, $.001 Par Value
  
“IONS”
  
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
  Emerging growth company                ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 2.02
Results of Operations and Financial Condition.
 
On May 6, 2020, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2020. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (GAAP), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation related to stock awards. The Company is presenting pro forma information excluding non-cash compensation related to stock awards because the Company believes it is useful for investors in assessing the Company’s operating results compared to the prior year.  A copy of the release is furnished with this report as an exhibit pursuant to “Item 2.02. Results of Operations and Financial Condition” of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583.
 
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
 
Item 9.01.
Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit No.
Description
Press Release dated May 6, 2020.
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Ionis Pharmaceuticals, Inc.
   
Dated:  May 6, 2020
By:
/s/ Patrick R. O’Neil
   
Patrick R. O’Neil
   
Senior Vice President, Legal, General Counsel and Chief Compliance Officer


EX-99.1 2 ex99_1.htm EXHIBIT 99.1
Exhibit 99.1


Ionis reports first quarter 2020 financial results and recent business achievements

On track to achieve 2020 financial guidance
 
Webcast today, May 6, 2020, at 11:30 a.m. Eastern Time
 
CARLSBAD, Calif., May 6, 2020 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2020 and recent business highlights.
 
“We achieved numerous value-driving catalysts in the first quarter, setting us up to achieve our strategic objectives for the year. Our commercial medicines continued to perform well, led by SPINRAZA. Our late-stage pipeline continues to advance, and we are particularly pleased that the tominersen Phase 3 study is fully enrolled, bringing us closer to potentially delivering this medicine to patients with Huntington’s disease. Additionally, AKCEA-APO(a)-LRx was granted fast track designation in the U.S., underscoring the significant value this medicine could deliver to the millions of patients with Lp(a)-driven cardiovascular disease,” said Brett P. Monia, chief executive officer at Ionis. “Thanks to the commitment and resilience of our employees, we delivered strong first quarter results while effectively managing the challenges inherent with the global COVID-19 pandemic, keeping us on track to achieve our 2020 goals. We plan to initiate the pivotal study for AKCEA-APOCIII-LRx in patients with FCS, bringing us to six pivotal studies underway this year. We also plan to refile the WAYLIVRA U.S. NDA and report additional proof-of-concept data from several of our programs this year. Our significant financial strength enables us to invest in our highest priorities, including advancing our Ionis-owned pipeline and our technology, and strengthening our commercial capabilities. Together, these achievements keep us positioned to deliver NDAs for ten or more of our medicines through 2025.”
 
Financial Results and Highlights
 
“We are reaffirming our 2020 financial guidance, including ending 2020 meaningfully profitable. We expect our results to be driven by continued significant commercial revenue and R&D revenue from numerous programs,” said Elizabeth L. Hougen, chief financial officer of Ionis. “We remain well-capitalized, with a strong balance sheet and $2.4 billion in cash and investments. Enabled by our financial strength, we have the resources to execute on our near- and longer-term strategic priorities, even in the challenging COVID-19 pandemic environment.”
 

 •
Growing commercial revenues combined with a substantial base of R&D revenues

o
Commercial revenue from SPINRAZA® (nusinersen) royalties increased by more than 10 percent to $66 million compared to Q1 2019

o
Product sales from TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen) more than doubled to $15 million compared to Q1 2019

o
R&D revenue of $49 million included over $25 million from Ionis’ neurology disease franchise and $15 million from its cardiometabolic franchise


•
First quarter results in line with projections to be meaningfully profitable this year

o
Operating loss and net loss of $61 million and $48 million, respectively, on a GAAP basis

o
Non-GAAP operating loss and net loss of $20 million and $15 million, respectively


•
Cash position of $2.4 billion provides substantial financial strength to continue executing on strategic goals

1
All non-GAAP amounts referred to in this press release exclude non-cash compensation expense related to equity awards. Please refer to the reconciliation of non-GAAP and GAAP measures, which is provided later in this release.
 
Commercial Medicine Highlights
 
•
SPINRAZA: a global foundation-of-care for the treatment of spinal muscular atrophy (SMA) patients of all ages

o
Worldwide sales increased to $565 million in the first quarter, a 9 percent increase compared to the first quarter of 2019

o
Worldwide patients on treatment increased to approximately 10,800 at the end of the first quarter, including patients across commercial, expanded access and clinical trial settings

o
Patient treatment is underway in the Phase 2/3 DEVOTE study evaluating the safety, tolerability and potential to achieve even greater efficacy with a higher dose of SPINRAZA

o
Data from an independent study published in Lancet Neurology demonstrated statistically significant improvement in motor function with SPINRAZA treatment in teens and adults
 
•
TEGSEDI: launched in multiple markets for the treatment of hereditary transthyretin amyloidosis (hATTR) with polyneuropathy in adult patients

o
Commercially available in 12 countries

o
Launching in additional EU countries this year and expanding in Latin America through PTC Therapeutics

o
Results from the NEURO-TTR Phase 3 open-label extension study were published in the European Journal of Neurology
 
•
WAYLIVRA: launched in the EU as the only approved treatment for adults with genetically confirmed familial chylomicronemia syndrome (FCS) at high risk for pancreatitis

o
Launch progressing in Germany, Austria and through the ATU in France

o
Launching in additional EU countries this year
 
Pipeline Highlights
 
•
Roche completed enrollment in the global, GENERATION HD1 Phase 3 study in patients with Huntington’s disease
•
Initiated the CARDIO-TTRansform Phase 3 clinical trial for AKCEA-TTR-LRx in patients with TTR-mediated amyloid cardiomyopathy
•
Two medicines granted Fast Track Designation by the U.S. FDA

o
AKCEA-APO(a)-LRx for the treatment of cardiovascular disease due to elevated Lp(a) levels

o
IONIS-C9Rx for the treatment of C9orf72-ALS
•
Ionis generated more than $20 million as numerous partnered medicines advanced

o
$10 million from AstraZeneca for ION532, targeting APOL1 for the treatment of kidney disease

o
$7.5 million from Biogen for IONIS-MAPTRx for the treatment of Alzheimer’s disease

o
$5 million from Dynacure for IONIS-DNM2-2.5Rx for the treatment of centronuclear myopathies
•
Ionis and Akcea reported positive topline results for AKCEA-APOCIII-LRx and vupanorsen (AKCEA-ANGPTL3-LRx)
•
Results from the Phase 2 study of AKCEA-APO(a)-LRx in patients with Lp(a)-driven cardiovascular disease, highlighting the favorable safety and tolerability profile and the potential to address a major area of unmet need, were published in the New England Journal of Medicine
•
Initiated a Phase 1 study of ION224, an Ionis-owned medicine in development for the treatment of NASH
 
Upcoming Catalysts
 
•
Initiate the Phase 3 study of AKCEA-APOCIII-LRx in patients with FCS
•
Refile WAYLIVRA new drug application for U.S. marketing authorization
•
File for WAYLIVRA marketing approval in Brazil with PTC Therapeutics
•
Report clinical proof-of-concept results for four or more programs

2
•
Initiate a first-in-human study of ION541 in patients with sporadic ALS, conducted by Biogen
•
Advance five or more new medicines into development, including several Ionis-owned medicines
 
Revenue
 
Ionis' revenue was comprised of the following (amounts in millions):
 
   
Three months ended,
March 31,
  
   
2020
    
2019
  
Revenue:
      
Commercial revenue:
            
SPINRAZA royalties
  
$
66
    
$
60
  
Product sales, net
    
15
      
7
  
Licensing and royalty revenue
    
3
      
1
  
Total commercial revenue
    
84
      
68
  
R&D Revenue:
                
Amortization from upfront payments
    
21
      
36
  
Milestone payments
    
23
      
40
  
License fees
    
-
      
150
  
Other services
    
5
      
3
  
Total R&D revenue
    
49
      
229
  
Total revenue
  
$
133
    
$
297
  
 
R&D revenue in the first quarter of 2019 included $185 million from two large items, including $150 million for the license of AKCEA-APO(a)-LRx.

Operating Expenses
 
Operating expenses increased for the first quarter of 2020, compared to the same period in 2019, principally due to Ionis’ investments in the global launches of TEGSEDI and WAYLIVRA, the Phase 3 program for AKCEA-TTR-LRx and the Company’s Ionis-owned pipeline.

Income Tax Expense (Benefit)
 
Ionis recorded an income tax benefit in the first quarter of 2020, compared to income tax expense in the same period in 2019. Ionis recorded an income tax benefit in the first quarter of 2020 because it generated a pre-tax loss.

Net (Income) Loss Attributable to Noncontrolling Interest in Akcea
 
At March 31, 2020, Ionis owned approximately 76 percent of Akcea. The shares of Akcea third parties own represent an interest in Akcea's equity that Ionis does not control. However, because Ionis continues to maintain overall control of Akcea through its voting interest, Ionis reflects the assets, liabilities and results of operations of Akcea in Ionis' consolidated financial statements. Ionis reflects the noncontrolling interest attributable to other owners of Akcea's common stock in a separate line called "Net (income) loss attributable to noncontrolling interest in Akcea" on Ionis' statement of operations. Ionis recognized a net loss attributable to noncontrolling interest in Akcea in the first quarter of 2020 compared to net income in the first quarter of 2019.  Net income attributable to noncontrolling interest in Akcea in the first quarter of 2019 was due to the significant license fee revenue Akcea earned when Novartis licensed AKCEA-APO(a)-LRx.

3
Net Income (Loss) Attributable to Ionis Common Stockholders
 
Ionis’ net loss attributable to Ionis’ common stockholders for the first quarter of 2020 was primarily due to Ionis’ investments in advancing its strategic priorities. Ionis’ net income attributable to Ionis’ common stockholders for the first quarter of 2019 was primarily due to the $150 million in revenue the Company earned when Novartis licensed AKCEA-APO(a)-LRx combined with lower operating expenses compared to the first quarter of 2020.

Balance Sheet

Ionis ended the first quarter of 2020 with cash, cash equivalents and short-term investments of $2.4 billion, nearly flat compared to $2.5 billion at December 31, 2019. During the first quarter of 2020, Ionis repurchased 1.5 million shares of its common stock under its share repurchase program for a total purchase price of $91 million.

Webcast

Today, at 11:30 a.m. Eastern Time, Ionis will conduct a live webcast to discuss this earnings release and related activities. Interested parties may access the webcast here. A webcast replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals, Inc.
 
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to potentially treat a broad range of diseases, including neurological, cardiovascular, infectious, and pulmonary diseases.

To learn more about Ionis visit www.ionispharma.com or follow us on twitter @ionispharma.

*Spinraza is marketed by Biogen.

Ionis’ Forward-looking Statement
 
This press release includes forward-looking statements regarding Ionis’ business, financial guidance and the therapeutic and commercial potential of SPINRAZA (nusinersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' majority-owned affiliate. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2019, which is on file with the SEC. Copies of this and other documents are available from the Company.

4
In this press release, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark of Akcea Therapeutics, Inc. TEGSEDI® is a registered trademark of Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of Akcea Therapeutics, Inc. SPINRAZA® is a registered trademark of Biogen.

Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D.
Vice President, Investor Relations
760-603-2741

Ionis Pharmaceuticals Media Contact:
Roslyn Patterson
Vice President, Corporate Communications
760-603-2681

5
IONIS PHARMACEUTICALS, INC.
SELECTED FINANCIAL INFORMATION
Condensed Consolidated Statements of Operations
(In Millions, Except Per Share Data)

   
Three months ended
March 31,
  
   
2020
    
2019
  
             
   
(unaudited)
  
Revenue:
            
Commercial revenue:
            
SPINRAZA royalties
  
$
66
    
$
60
  
Product sales, net
    
15
      
7
  
Licensing and royalty revenue
    
3
      
1
  
Total commercial revenue
    
84
      
68
  
Research and development revenue under collaborative agreements
    
49
      
229
  
Total revenue
    
133
      
297
  
Expenses:
                
Cost of products sold
    
3
      
1
  
Research, development and patent
    
116
      
107
  
Selling, general and administrative
    
75
      
68
  
Total operating expenses
    
194
      
176
  
Income (loss) from operations
    
(61
)
    
121
  
Other income (expense):
                
Investment income
    
10
      
12
  
Interest expense
    
(11
)
    
(12
)
Income (loss) before income tax benefit (expense)
    
(62
)
    
121
  
                 
Income tax benefit (expense)
    
3
      
(31
)
                 
Net income (loss)
  
$
(59
)
  
$
90
  
Net (income) loss attributable to noncontrolling interest in Akcea Therapeutics, Inc.
    
11
      
(6
)
Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders
  
$
(48
)
  
$
84
  
                 
Basic net income (loss) per share
  
$
(0.35
)
  
$
0.63
  
Diluted net income (loss) per share
  
$
(0.35
)
  
$
0.62
  
Shares used in computing basic net income (loss) per share
    
139,429
      
138,582
  
Shares used in computing diluted net income (loss) per share
    
139,429
      
141,537
  

6
IONIS PHARMACEUTICALS, INC.
SELECTED FINANCIAL INFORMATION
Condensed Consolidating Statement of Operations
(In Millions)

   
Three months ended,
March 31, 2020
(unaudited)
  
   
Ionis
    
Akcea
    
Eliminations
    
Ionis
Consolidated
  
Revenue:
      
Commercial revenue:
                        
SPINRAZA royalties
  
$
$66
    
$
-
    
$
-
    
$
66
  
Product sales, net
    
-
      
15
      
-
      
15
  
Licensing and royalty revenue
    
3
      
-
      
-
      
3
  
Total commercial revenue
    
69
      
15
      
-
      
84
  
Research and development revenue under collaborative agreements
    
48
      
1
      
-
      
49
  
Intercompany revenue
    
1
      
-
      
(1
)
    
-
  
Total revenue
    
118
      
16
      
(1
)
    
133
  
Expenses:
                                
Cost of products sold
    
-
      
5
      
(2
)
    
3
  
Research, development and patent expenses
    
99
      
17
      
-
      
116
  
Selling, general and administrative
    
29
      
46
      
-
      
75
  
Profit/ loss share for TEGSEDI commercialization activities
    
7
      
(7
)
    
-
      
-
  
Total operating expenses
    
135
      
61
      
(2
)
    
194
  
                                 
Loss from operations
    
(17
)
    
(45
)
    
1
      
(61
)
                                 
Other income (expense):
                                
Investment income
    
9
      
1
      
-
      
10
  
Interest expense
    
(11
)
    
-
      
-
      
(11
)
Loss on early retirement of debt
    
-
      
-
      
-
      
-
  
Loss before income tax benefit
    
(19
)
    
(44
)
    
1
      
(62
)
                                 
Income tax benefit
    
2
      
1
      
-
      
3
  
                                 
Net loss
  
$
(17
)
  
$
(43
)
  
$
1
    
$
(59
)
Net loss attributable to noncontrolling interest in Akcea Therapeutics, Inc.
  
$
-
    
$
-
    
$
11
    
$
11
  
Net loss attributable to Ionis Pharmaceuticals, Inc. common stockholders
  
$
(17
)
  
$
(43
)
  
$
12
    
$
(48
)

7
IONIS PHARMACEUTICALS, INC.

Reconciliation of GAAP to Non-GAAP Basis:
Condensed Consolidated Operating Expenses, Income (Loss) From Operations, and Net Income (Loss)
(In Millions)
 
   
Three months ended,
March 31,
  
   
2020
    
2019
  
   
(unaudited)
  
As reported research, development and patent expenses according to GAAP
  
$
116
    
$
107
  
Excluding compensation expense related to equity awards
    
(26
)
    
(25
)
                 
Non-GAAP research, development and patent expenses
  
$
90
    
$
82
  
As reported selling, general and administrative expenses according to GAAP
  
$
75
    
$
68
  
Excluding compensation expense related to equity awards
    
(15
)
    
(21
)
                 
Non-GAAP selling, general and administrative expenses
  
$
60
    
$
47
  
As reported operating expenses according to GAAP
  
$
194
    
$
176
  
Excluding compensation expense related to equity awards
    
(41
)
    
(46
)
                 
Non-GAAP operating expenses
  
$
153
    
$
130
  
                 
As reported income (loss) from operations according to GAAP
  
$
(61
)
  
$
121
  
Excluding compensation expense related to equity awards
    
(41
)
    
(46
)
Non-GAAP income (loss) from operations
  
$
(20
)
  
$
167
  
As reported net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders according to GAAP
  
$
(48
)
  
$
84
  
Excluding compensation expense related to equity awards attributable to Ionis Pharmaceuticals, Inc. common stockholders
    
(39
)
    
(42
)
Income tax effect related to compensation expense related to equity awards attributable to Ionis Pharmaceuticals, Inc. common stockholders
    
6
      
(1
)
Non-GAAP net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders according to GAAP
  
$
(15
)
  
$
127
  

8
Reconciliation of GAAP to Non-GAAP Basis
 
As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP income (loss) from operations, and non-GAAP net income (loss) attributable to Ionis Pharmaceuticals, Inc. common shareholders were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effect. Compensation expense related to equity awards are non-cash. Ionis has regularly reported non-GAAP measures for operating results as non-GAAP results. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Ionis' non-GAAP results is consistent with how Ionis' management internally evaluates the performance of its operations.
 
9
IONIS PHARMACEUTICALS, INC.
Condensed Consolidated Balance Sheets
(In Millions)
 
   
March 31,
2020
    
December 31,
2019
  
   
(unaudited)
        
Assets:
            
Cash, cash equivalents and short-term investments
  
$
2,384
    
$
2,500
  
Contracts receivable
    
29
      
63
  
Other current assets
    
145
      
158
  
Property, plant and equipment, net
    
164
      
154
  
Other assets
    
369
      
358
  
Total assets
  
$
3,091
    
$
3,233
  
                 
Liabilities and stockholders’ equity:
                
Other current liabilities
  
$
137
    
$
155
  
Current portion of deferred contract revenue
    
121
      
118
  
0.125% convertible senior notes
    
440
      
435
  
1% convertible senior notes
    
280
      
275
  
Long-term obligations, less current portion
    
75
      
75
  
Long-term deferred contract revenue
    
468
      
490
  
Total Ionis stockholders’ equity
    
1,360
      
1,471
  
Noncontrolling interest in Akcea Therapeutics, Inc.
    
210
      
214
  
Total stockholders’ equity
    
1,570
      
1,685
  
Total liabilities and stockholders’ equity
  
$
3,091
    
$
3,233
  

10
IONIS PHARMACEUTICALS, INC.
Condensed Consolidating Balance Sheet
(In Millions)

   
March 31, 2020
(unaudited)
  
   
Ionis
    
Akcea
    
Eliminations
    
Ionis
Consolidated
  
                         
Assets:
                        
Cash, cash equivalents and short-term investments
  
$
1,963
    
$
421
    
$
-
    
$
2,384
  
Contracts receivable
    
17
      
12
      
-
      
29
  
Other current assets
    
121
      
26
      
(2
)
    
145
  
Property, plant and equipment, net
    
159
      
5
      
-
      
164
  
Other assets
    
1,116
      
96
      
(843
)
    
369
  
Total assets
  
$
3,376
    
$
560
    
$
(845
)
  
$
3,091
  
                                 
Liabilities and stockholders’ equity:
                                
Other current liabilities
    
104
      
35
      
(2
)
    
137
  
Current portion of deferred contract revenue
    
120
      
1
      
-
      
121
  
0.125% convertible senior notes
    
440
      
-
      
-
      
440
  
1% convertible senior notes
    
280
      
-
      
-
      
280
  
Long-term obligations, less current portion
    
61
      
14
      
-
      
75
  
Long-term deferred contract revenue
    
470
      
-
      
(2
)
    
468
  
Total stockholders’ equity before noncontrolling interest
    
1,901
      
510
      
(1,051
)
    
1,360
  
Noncontrolling interest in Akcea Therapeutics, Inc.
    
-
      
-
      
210
      
210
  
Total stockholders’ equity
  
$
1,901
    
$
510
    
$
(841
)
  
$
1,570
  
Total liabilities and stockholders’ equity
  
$
3,376
    
$
560
    
$
(845
)
  
$
3,091
  


11
EX-101.SCH 3 ions-20200506.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ions-20200506_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Amendment Flag City Area Code Entity Address, City or Town Entity Address, Country Document Period End Date Entity Incorporation, State or Country Code Local Phone Number Entity Address, Postal Zip Code Entity Address, State or Province Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Document Fiscal Year Focus Document Fiscal Period Focus Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity File Number Entity Emerging Growth Company EX-101.PRE 5 ions-20200506_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image0.jpg begin 644 image0.jpg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end XML 7 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://isispharm.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports form8k.htm ex99_1.htm ions-20200506.xsd ions-20200506_lab.xml ions-20200506_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 9 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "form8k.htm" ] }, "labelLink": { "local": [ "ions-20200506_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ions-20200506_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ions-20200506.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ions", "nsuri": "http://isispharm.com/20200506", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20200506to20200506", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://isispharm.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20200506to20200506", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://isispharm.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 11 0001140361-20-010790-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-20-010790-xbrl.zip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end EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
May 06, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 06, 2020
Entity Registrant Name IONIS PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 000-19125
Entity Tax Identification Number 33-0336973
Entity Address, Address Line One 2855 Gazelle Court
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92010
City Area Code 760
Local Phone Number 931-9200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000874015
Title of 12(b) Security Common Stock, $.001 Par Value
Trading Symbol IONS
Security Exchange Name NASDAQ
XML 15 form8k_htm.xml IDEA: XBRL DOCUMENT 0000874015 2020-05-06 2020-05-06 false 0000874015 8-K 2020-05-06 IONIS PHARMACEUTICALS, INC. DE 000-19125 33-0336973 2855 Gazelle Court Carlsbad CA 92010 760 931-9200 false false false false Common Stock, $.001 Par Value IONS NASDAQ false